<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical presentation, diagnosis, and course of primary vesicoureteral reflux</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical presentation, diagnosis, and course of primary vesicoureteral reflux</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Clinical presentation, diagnosis, and course of primary vesicoureteral reflux</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Tej K Mattoo, MD, DCH, FRCP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Saul P Greenfield, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Laurence S Baskin, MD, FAAP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">F Bruder Stapleton, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alison G Hoppin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 24, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The clinical significance of vesicoureteral reflux (VUR) has been based on the premise that VUR predisposes patients to acute pyelonephritis by transporting bacteria from the bladder to the kidney, which may lead to kidney scarring, hypertension, and chronic kidney disease (CKD). However, aspects of this long-held belief about VUR have been increasingly questioned. As a result, the clinical impact of VUR and its management remain uncertain and controversial.</p><p>The presentation, diagnosis, and clinical course of primary VUR will be reviewed here. The management of primary VUR is discussed separately. (See  <a class="medical medical_review" href="/d/html/6095.html" rel="external">"Management of vesicoureteral reflux"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">DEFINITION AND PATHOGENESIS</span><span class="headingEndMark"> — </span>VUR is the retrograde passage of urine from the bladder into the upper urinary tract. It is divided into two categories: primary and secondary based on the underlying pathogenesis.</p><p class="headingAnchor" id="H3"><span class="h2">Primary VUR</span><span class="headingEndMark"> — </span>Primary VUR, the most common form of reflux, is due to incompetent or inadequate closure of the ureterovesical junction (UVJ), which contains a segment of the ureter within the bladder wall (intravesical ureter). Normally, reflux is prevented during bladder contraction by fully compressing the intravesical ureter and sealing it off with the surrounding bladder muscles.</p><p>In primary VUR, failure of this anti-reflux mechanism is due to a congenitally short intravesical ureter  (<a class="graphic graphic_figure graphicRef54236" href="/d/graphic/54236.html" rel="external">figure 1</a>). The intravesical ureter length may be genetically determined, which may explain the increased incidence in family members of patients with VUR.</p><p>Spontaneous resolution of primary low-grade VUR commonly occurs with patient growth [<a href="#rid1">1</a>]. As the bladder grows, the intravesical ureter increases in length, improving the function of the anti-reflux mechanism. (See <a class="local">'Natural history'</a> below.)</p><p class="headingAnchor" id="H4"><span class="h2">Secondary VUR</span><span class="headingEndMark"> — </span>Secondary VUR is a result of abnormally high voiding pressure in the bladder that results in failure of the closure of the UVJ during bladder contraction. Secondary VUR is often associated with anatomic (eg, posterior urethral valves) or functional bladder obstruction (eg, bladder bowel dysfunction [BBD] and neurogenic bladder) [<a href="#rid2">2</a>]. The degree and chronicity of obstruction can influence the severity of VUR. (See  <a class="medical medical_review" href="/d/html/6575.html" rel="external">"Clinical presentation and diagnosis of posterior urethral valves", section on 'Vesicoureteral reflux'</a> and  <a class="medical medical_review" href="/d/html/6209.html" rel="external">"Myelomeningocele (spina bifida): Urinary tract complications"</a>.)</p><p class="headingAnchor" id="H5"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Primary VUR is the most common urologic finding in children, occurring in approximately 1 percent of newborns [<a href="#rid3">3</a>]. The prevalence increases for neonates with prenatal hydronephrosis (up to 15 percent) [<a href="#rid4">4,5</a>], and for children with febrile urinary tract infections (UTIs) (ranging from 30 to 45 percent) [<a href="#rid6">6</a>].</p><p>The risk for primary VUR varies based on ethnicity, sex, and age. This was shown in a retrospective study from a single urban center in the United States that diagnosed VUR in 3661 of 15,504 children who were screened by a voiding cystourethrogram (VCUG) [<a href="#rid7">7</a>]. The following observations were made:</p><p class="bulletIndent1"><span class="glyph">●</span>Ethnicity – White children were three times more likely to have VUR than Black children. The maximal grade of reflux was significantly lower in Black children.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sex – In this cohort, females were twice as likely to have reflux as males. However, the sex difference is smaller in countries where circumcision is not routinely performed [<a href="#rid8">8,9</a>]. In contrast, there is a male predominance in patients who present with prenatal hydronephrosis [<a href="#rid3">3,10</a>]. (See <a class="local">'Natural history'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Age – Young children and infants (younger than two years of age) were more likely to have VUR than older children as there is spontaneous resolution with growth in the majority of affected children. (See <a class="local">'Natural history'</a> below.)</p><p></p><p>In the United States, the predominance of female sex and White ethnicity appears to be greater in the subset of young children who are diagnosed after an episode of UTI. This was illustrated in the Randomized Intervention for Vesicoureteral Reflux (RIVUR) trial that reported that 81 percent of the 607 children with VUR diagnosed after febrile and/or symptomatic UTI were White and 92 percent were females [<a href="#rid11">11</a>]. In contrast, there is a male predominance in patients with prenatal presentation. In Europe and Asia, male predominance persists through early infancy most likely because neonatal circumcision is less commonly performed, resulting in a higher incidence of UTI, which may prompt an evaluation for VUR. (See <a class="local">'Clinical presentation'</a> below and  <a class="medical medical_review" href="/d/html/5988.html" rel="external">"Urinary tract infections in children: Epidemiology and risk factors", section on 'Lack of circumcision'</a>.)</p><p class="headingAnchor" id="H6"><span class="h1">GENETICS</span><span class="headingEndMark"> — </span>There is a genetic predisposition for primary vesicoureteral reflux (VUR), as documented by a systematic review that found prevalence rates of 27.4 percent for siblings of a patient with VUR, and 35.7 percent for children of an affected parent [<a href="#rid5">5</a>]. The risk of VUR decreased as the age of the screened family member increased, at an estimated annual resolution rate of 4 percent. The familial rate was lower for more severe compared with milder forms of VUR (9.8 percent for Grades III to IV versus 16.7 percent for Grades I to II). (See <a class="local">'Grading'</a> below.)</p><p>Additional data supporting a genetic predisposition was provided by a small study of multiple gestation births that found a higher VUR rate in identical twins (12 out of 15 twin sets, 80 percent) compared with fraternal twins (11 out of 31 twin sets, 35 percent) [<a href="#rid12">12</a>].</p><p>Primary VUR appears to be genetically heterogeneous. </p><p class="bulletIndent1"><span class="glyph">●</span>In a study of 460 families, parametric linkage analysis using a dominant model revealed linkage to a region on chromosome 10q26 encompassing 69 genes [<a href="#rid13">13</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A second study using a similar approach for a large 97-member family with VUR and joint hypermobility, mapped the disorder to a locus on chromosome 6p [<a href="#rid14">14</a>]. Using whole exome sequencing, they identified a causal heterozygous missense variant in <em>Tenascin XB</em>, <em>TNXB</em>, a large extracellular matrix protein that regulates collagen deposition, indicating that perturbations in the extracellular matrix that supports the ureterovesical junction may predispose to VUR. These results are particularly compelling since VUR is associated with joint hypermobility in some children [<a href="#rid15">15</a>].</p><p></p><p>Research studies have also suggested a genetic susceptibility of individuals to kidney scarring, which may explain the variability in scarring in many children with VUR [<a href="#rid16">16,17</a>]. A study examined copy number variants in children from the RIVUR cohort and found that copy number variants (CNVs) implicated in the innate immune response were enriched in children with VUR compared with age- and ethnicity-matched controls [<a href="#rid18">18</a>].</p><p class="headingAnchor" id="H759413688"><span class="h1">CLINICAL PRESENTATION</span></p><p class="headingAnchor" id="H2169428111"><span class="h2">Prenatal presentation</span><span class="headingEndMark"> — </span>The presence of VUR is suggested by the finding of hydronephrosis on prenatal ultrasonography. (See  <a class="medical medical_review" href="/d/html/6099.html" rel="external">"Fetal hydronephrosis: Etiology and prenatal management"</a> and  <a class="medical medical_review" href="/d/html/6105.html" rel="external">"Postnatal evaluation and management of hydronephrosis"</a>.)</p><p>In the available reports, approximately 10 to 40 percent of infants with prenatally diagnosed hydronephrosis were found to have VUR [<a href="#rid4">4,5</a>]. </p><p>In a systematic review that included 34 observational studies, the pooled prevalence of VUR among infants with prenatally diagnosed hydronephrosis was 16 percent [<a href="#rid5">5</a>]. Renal pelvic diameter (RPD) was not predictive of VUR as the etiology. </p><p>There is a male predominance in patients with VUR who present prenatally. In one study of 155 consecutive infants with VUR, 75 percent were males, and patients with Grade V reflux were almost exclusively male [<a href="#rid10">10</a>]. </p><p class="headingAnchor" id="H1094825518"><span class="h2">Postnatal presentation</span><span class="headingEndMark"> — </span>Postnatal diagnosis of VUR is usually made after a diagnosis of a febrile UTI, and less commonly after family screening. (See  <a class="medical medical_review" href="/d/html/5991.html" rel="external">"Urinary tract infections in infants older than one month and children less than two years: Acute management, imaging, and prognosis", section on 'Imaging'</a> and <a class="local">'Testing family members'</a> below.)</p><p>Older toilet-trained children, especially females, with VUR diagnosed after an initial UTI have a higher likelihood of having bowel and bladder dysfunction (BBD) [<a href="#rid19">19-23</a>]. (See  <a class="medical medical_review" href="/d/html/6095.html" rel="external">"Management of vesicoureteral reflux", section on 'Bladder and bowel dysfunction'</a>.)</p><p class="headingAnchor" id="H3454276382"><span class="h1">EVALUATION</span></p><p class="headingAnchor" id="H3663951993"><span class="h2">Infants with prenatally diagnosed hydronephrosis</span><span class="headingEndMark"> — </span>The evaluation of infants with prenatally diagnosed hydronephrosis is summarized in the figures  (<a class="graphic graphic_algorithm graphicRef69172 graphicRef74670" href="/d/graphic/69172.html" rel="external">algorithm 1A-B</a>) and discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/6105.html" rel="external">"Postnatal evaluation and management of hydronephrosis"</a>.)</p><p class="headingAnchor" id="H2309438512"><span class="h2">Infants and children presenting with UTI</span><span class="headingEndMark"> — </span>The evaluation for VUR in children with urinary tract infections (UTIs) is controversial, as evidence to support the utility of routine imaging for reducing long-term sequelae (kidney scarring, hypertension, kidney failure) is limited and inconclusive. (See  <a class="medical medical_review" href="/d/html/5991.html" rel="external">"Urinary tract infections in infants older than one month and children less than two years: Acute management, imaging, and prognosis", section on 'Imaging'</a>.)</p><p>When imaging is pursued, the initial test is usually a kidney and bladder ultrasound, which assesses the size and shape of the kidneys, and detects any kidney anatomical abnormality. Indications for performing ultrasonography after a UTI are discussed separately. (See  <a class="medical medical_review" href="/d/html/5991.html" rel="external">"Urinary tract infections in infants older than one month and children less than two years: Acute management, imaging, and prognosis", section on 'Ultrasonography'</a>.)</p><p>The next step in the evaluation for VUR is usually a voiding cystourethrogram (VCUG). Indications for performing a VCUG after a UTI in infants and children are reviewed separately. (See  <a class="medical medical_review" href="/d/html/5991.html" rel="external">"Urinary tract infections in infants older than one month and children less than two years: Acute management, imaging, and prognosis", section on 'Voiding cystourethrogram'</a>.)</p><p class="headingAnchor" id="H854005885"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of VUR is established with contrast voiding cystourethrogram (VCUG) demonstrating reflux of urine from the bladder to the upper urinary tract. Alternative imaging modalities that are uncommonly used to diagnose VUR include contrast-enhanced voiding urosonography (ceVUS) or radionuclide cystogram (RNC). (See <a class="local">'Imaging'</a> below.)</p><p class="headingAnchor" id="H435183022"><span class="h2">Imaging</span></p><p class="headingAnchor" id="H4082697602"><span class="h3">VCUG versus RNC</span><span class="headingEndMark"> — </span>The voiding cystourethrogram (VCUG) is the test of choice to establish the presence and degree of VUR. Radionuclide cystogram (RNC) is an alternative modality. However, despite the increased radiation exposure associated with VCUG, VCUG provides greater anatomic detail. Specifically, RNC does not reliably show bladder wall appearance or Grade I reflux. RNC also does not demonstrate urethral anatomy in boys, which may be important in secondary causes of VUR (eg, posterior urethral valves). For this reason, in many centers (including ours), RNC is not used as the initial study, but may be used to monitor for persistent reflux in follow up studies.</p><p>If a VCUG or RNC is performed in infants and young children, the procedure needs to be done in referral centers that have expertise both in catheterization and, in the case of VCUG, determination and minimization of radiation exposure. In these settings, the complications of the procedures can be reduced by using standardized protocol developed by the Urology and Radiology sections of the American Academy of Pediatrics (AAP), which focuses on patient safety by minimizing radiation exposure [<a href="#rid24">24,25</a>].</p><p class="headingAnchor" id="H3617932272"><span class="h3">CeVUS (contrast-enhanced voiding urosonography)</span><span class="headingEndMark"> — </span>Contrast-enhanced voiding urosonography is a relatively new technique employing an ultrasonographic contrast agent to image the lower urinary tract and detect VUR. Although catheterization is still necessary, this technique avoids radiation. It may be more sensitive in detecting some low-grade reflux, and it can be used to image the urethra in males. Further study of this modality is needed to determine whether there is a role for this imaging technique in detecting VUR. In addition, it would not be possible to assess the ureteral diameter ratio (UDR) with this technique (see below).</p><p class="headingAnchor" id="H8"><span class="h3">Grading</span><span class="headingEndMark"> — </span>The International Reflux Study Group (IRSG) developed a classification system that grades the severity of VUR based upon the degree of retrograde filling and dilation of the renal collecting system demonstrated by VCUG  (<a class="graphic graphic_figure graphicRef67039" href="/d/graphic/67039.html" rel="external">figure 2</a>) [<a href="#rid26">26</a>]. It is important to note the subjectivity of assigning VUR grades because there is not perfect concordance even among expert readers, especially when differentiating between intermediate grades (II and III) [<a href="#rid27">27,28</a>]. This has implications when interpreting the literature and when making individual treatment decisions. In addition, it is important to use a standardized protocol for VCUG as changes in test parameters can influence test results. In our centers, we utilized the protocol developed by the AAP [<a href="#rid25">25</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Grade I – Reflux only fills the ureter without dilation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Grade II – Reflux fills the ureter and the collecting system without dilation  (<a class="graphic graphic_diagnosticimage graphicRef58470" href="/d/graphic/58470.html" rel="external">image 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Grade III – Reflux fills and mildly dilates the ureter and the collecting system with mild blunting of the calices.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Grade IV – Reflux fills and grossly dilates the ureter and the collecting system with blunting of the calices. Some tortuosity of the ureter is also present.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Grade V – Massive reflux grossly dilates the collecting system. All the calices are blunted with a loss of papillary impression, and intrarenal reflux may be present  (<a class="graphic graphic_diagnosticimage graphicRef53390" href="/d/graphic/53390.html" rel="external">image 2</a>). There is significant ureteral dilation and tortuosity.</p><p></p><p>In the literature, the severity of reflux has been organized into two different classifications.</p><p>The first classification:</p><p class="bulletIndent1"><span class="glyph">●</span>Mild – Grades I and II</p><p class="bulletIndent1"><span class="glyph">●</span>Moderate – Grade III</p><p class="bulletIndent1"><span class="glyph">●</span>Severe – Grades IV and V</p><p></p><p>VUR has also been divided into:</p><p class="bulletIndent1"><span class="glyph">●</span>Low – Grades I through III</p><p class="bulletIndent1"><span class="glyph">●</span>High – Grades IV and V</p><p></p><p>A system based upon RNC findings utilizes three grades and correlates with the IRSG VUR grades as follows  (<a class="graphic graphic_picture graphicRef74445" href="/d/graphic/74445.html" rel="external">picture 1</a>) [<a href="#rid29">29</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Grade 1 for mild reflux – VUR Grade I</p><p class="bulletIndent1"><span class="glyph">●</span>Grade 2 for moderate reflux – VUR Grades II and III</p><p class="bulletIndent1"><span class="glyph">●</span>Grade 3 for severe reflux – VUR Grades IV and V</p><p></p><p>The use of distal ureteral diameter ratio (UDR) has been promoted to grade VUR and eliminate the subjectivity of the IRSG system [<a href="#rid30">30-32</a>]. In this proposed schema, the pelvic ureteral width is measured at its greatest diameter and compared with the spinal distance between the bottom of L1 and the top of L3. The UDR has been shown to have better interobserver reliability, and appears to be a better predictor of outcome. Preliminary data have shown children with a lower UDR had fewer breakthrough infections over time, independent of the grade of VUR or the presence of bowel and bladder dysfunction (BBD), and UDR more accurately predicted surgical intervention, and spontaneous resolution of VUR with growth correlated well with the calculated UDR. However, further research is needed to validate these findings before this system is adopted to either replace or complement the grading system currently in use.</p><p>A Vesicoureteral Reflux Index has been proposed as another tool to predict clinical outcomes and ultimate resolution with somatic growth. The index is a six-point scale based upon sex, reflux grade, ureteral abnormalities, and reflux timing. Index scores have been predictive of breakthrough infection, grade improvement over time, and resolution [<a href="#rid33">33,34</a>]. Validation of this scoring system needs to be performed in other cohorts prior to its routine use in clinical practice. </p><p class="headingAnchor" id="H416212810"><span class="h3">Other imaging modalities</span><span class="headingEndMark"> — </span>Other imaging techniques have been proposed that either eliminate the need for catheterization and/or radiation exposure. These include ultrasound and <a class="drug drug_general" data-topicid="9102" href="/d/drug information/9102.html" rel="external">dimercaptosuccinic acid</a> (DMSA) renal scan. However, a systematic review reported that neither kidney ultrasound nor DMSA renal scan is accurate enough to detect VUR of all grades in children with UTI [<a href="#rid35">35</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Kidney ultrasonography is limited in its sensitivity of detecting VUR, including cases of high-grade VUR, which may not demonstrate the associated findings of hydronephrosis or caliectasis. In the previously mentioned RIVUR trial of children with grades I to IV VUR, 90 percent of the initial kidney ultrasounds were normal [<a href="#rid11">11</a>]. (See  <a class="medical medical_review" href="/d/html/5991.html" rel="external">"Urinary tract infections in infants older than one month and children less than two years: Acute management, imaging, and prognosis", section on 'Ultrasonography'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Although DMSA renal scan is an accurate means of detecting kidney dysmorphology secondary to VUR-related congenital kidney hypodysplasia or scarring from infection, the absence of these findings does not rule out VUR, and even cases of moderate to severe VUR may not be detected. (See  <a class="medical medical_review" href="/d/html/5991.html" rel="external">"Urinary tract infections in infants older than one month and children less than two years: Acute management, imaging, and prognosis", section on 'Kidney scintigraphy'</a>.)</p><p></p><p>Indirect radionuclide or magnetic resonance imaging (MRI) cystography, thermal imaging after heating bladder urine with external devices, and the use of ultrasound with sonographic contrast agents are experimental modalities, which need to be confirmed as a cost-effective alternative to VCUG [<a href="#rid36">36-44</a>].</p><p class="headingAnchor" id="H1242525374"><span class="h2">Indirect lab tests: Not clinically useful</span><span class="headingEndMark"> — </span>Indirect urinary and serum markers (procalcitonin, cystatin C, urinary mRNA, C-reactive protein, matrix metalloproteinase 9, interleukins 6 and 8, and urinary proteome analysis) have been proposed as predictive tests for VUR; however, none of these methodologies are as accurate as cystography in making the diagnosis of VUR.</p><p class="headingAnchor" id="H4032662090"><span class="h1">FURTHER EVALUATION</span></p><p class="headingAnchor" id="H2589802512"><span class="h2">Index patient</span><span class="headingEndMark"> — </span>Because of the association between VUR and kidney scarring, which may lead to chronic kidney disease (CKD), we suggest the following evaluation for children diagnosed with VUR:</p><p class="bulletIndent1"><span class="glyph">●</span>Comprehensive physical examination, including measurement of height, weight, and blood pressure.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Laboratory assessment, including:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Urinalysis to detect proteinuria.</p><p></p><p class="bulletIndent2">If the urinalysis is positive for protein, a first morning urine protein/creatinine ratio should be performed because proteinuria may be an indication of significant CKD. (See  <a class="medical medical_review" href="/d/html/6091.html" rel="external">"Evaluation of proteinuria in children", section on 'Measurement of urinary protein'</a>.)</p><p></p><p class="bulletIndent2">If pyuria or bacteria are detected on urinalysis, an appropriate specimen should be collected and sent for urine culture. (See  <a class="medical medical_review" href="/d/html/5990.html" rel="external">"Urinary tract infections in infants and children older than one month: Clinical features and diagnosis", section on 'Urine culture'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Serum creatinine should be obtained if the child has bilateral kidney involvement or solitary kidney. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Kidney imaging – Kidney and bladder ultrasound should be performed, if not already done. Kidney ultrasound can identify anatomic abnormalities and may show evidence of renal scarring. <a class="drug drug_general" data-topicid="9102" href="/d/drug information/9102.html" rel="external">Dimercaptosuccinic acid</a> (DMSA) renal scan is superior in detecting renal cortical abnormalities compared with other imaging modalities and should be obtained in patients who are at risk for scarring or appear to have loss of renal parenchyma on kidney ultrasound. (See <a class="local">'Kidney scarring'</a> below and  <a class="medical medical_review" href="/d/html/5991.html" rel="external">"Urinary tract infections in infants older than one month and children less than two years: Acute management, imaging, and prognosis", section on 'Imaging'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Assessment for symptoms of bladder and bowel dysfunction (BBD), which can be associated with VUR and recurrent UTI in older, toilet-trained children. BBD also prolongs the time to spontaneous VUR resolution. As a result, the initial evaluation should identify if there are symptoms indicative of BBD (eg, urinary frequency and urgency, daytime wetting, constipation, and encopresis), so that interventions to improve bladder and bowel function can be initiated. (See  <a class="medical medical_review" href="/d/html/6577.html" rel="external">"Evaluation and diagnosis of bladder dysfunction in children"</a> and  <a class="medical medical_review" href="/d/html/6578.html" rel="external">"Management of bladder dysfunction in children"</a> and  <a class="medical medical_review" href="/d/html/6095.html" rel="external">"Management of vesicoureteral reflux", section on 'Bladder and bowel dysfunction'</a>.)</p><p></p><p>This approach is generally consistent with the 2010 revised guidelines from the American Urological Association (AUA) [<a href="#rid45">45</a>]. The guidelines were based on a systematic review of the available literature; however, the available studies were generally low quality. Links to these and other guidelines are provided separately. (See <a class="local">'Society guideline links'</a> below.)</p><p class="headingAnchor" id="H1227800466"><span class="h2">Testing family members</span><span class="headingEndMark"> — </span>There is debate over the advantages and disadvantages of testing for VUR in family members because there are no data on the outcomes of treated versus untreated affected first-degree family members (ie, offspring or siblings) [<a href="#rid46">46</a>]. Our approach, which is consistent with the AUA guidelines, is to selectively test immediate family members with a kidney and bladder ultrasound and voiding cystourethrogram (VCUG) or radionuclide cystogram (RNC) [<a href="#rid5">5,47,48</a>]. We perform testing in younger siblings and offspring (under age five years) when there is a history of BBD or UTI, or if there is concern that the family/caregiver will not be compliant in seeking medical attention when there are symptoms suggestive of UTI or unexplained fever [<a href="#rid47">47,49</a>].</p><p>Although data are limited, available evidence suggest there is increased risk of kidney scarring in siblings of patients with high-grade VUR. In an observational study of 300 siblings of 259 patients with high-grade VUR (ie, Grades III to V), almost one-quarter of the 212 siblings who underwent DMSA renal scan had evidence of kidney scarring [<a href="#rid50">50</a>]. In a second publication from the same center, the risk for renal cortical abnormalities was increased in siblings with a previous UTI, siblings with high-grade reflux, and siblings who were over one year of age [<a href="#rid47">47</a>].</p><p class="headingAnchor" id="H16"><span class="h1">NATURAL HISTORY</span><span class="headingEndMark"> — </span>Most children with primary VUR have spontaneous resolution [<a href="#rid11">11,51-53</a>]. The likelihood of resolution is highest in children with low-grade unilateral reflux who are diagnosed at a young age (&lt;2 years)  (<a class="graphic graphic_figure graphicRef50469" href="/d/graphic/50469.html" rel="external">figure 3</a>) [<a href="#rid51">51-58</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span>Grades I and II – Approximately 70 to 80 percent of patients with grades I and II VUR have spontaneous resolution by five years of age [<a href="#rid51">51,53</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Grades III and IV – For children with grades III and IV VUR, the likelihood of spontaneous resolution varies depending on the age at presentation and whether VUR is unilateral or bilateral. In young children (&lt;2 years old) with unilateral VUR, the rate of spontaneous resolution is approximately 60 to 70 percent over five years [<a href="#rid51">51</a>]. By contrast, the rate of spontaneous resolution among older children (age 5 to 10 years) with bilateral reflux is approximately 10 to 20 percent over five years. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Grade V – Spontaneous resolution is rare [<a href="#rid54">54,55</a>].</p><p></p><p class="headingAnchor" id="H1934701667"><span class="h1">COMPLICATIONS</span></p><p class="headingAnchor" id="H33393660"><span class="h2">Recurrent urinary tract infection</span><span class="headingEndMark"> — </span>Children with VUR are at risk for recurrent febrile or symptomatic urinary tract infections (UTIs). Children with more severe grades of VUR, and those who have associated bladder and bowel dysfunction have the highest risk of recurrent symptomatic or febrile UTIs [<a href="#rid19">19,59</a>].</p><p>While UTI episodes are not always associated with kidney scarring, they are often associated with emergency department or clinic visits, hospitalizations, loss of school days, and loss of work for caregivers. </p><p>In a clinical trial evaluating the efficacy and safety of prophylactic antibiotics in children with VUR, febrile or symptomatic UTIs occurred more commonly in children with Grade III or IV VUR compared with Grade I or II VUR (23 versus 14 percent over the two-year study follow-up) [<a href="#rid11">11</a>]. (See  <a class="medical medical_review" href="/d/html/6095.html" rel="external">"Management of vesicoureteral reflux", section on 'Antibiotic prophylaxis'</a>.)</p><p class="headingAnchor" id="H33392088"><span class="h2">Loss of renal parenchyma</span><span class="headingEndMark"> — </span>Kidney scarring can cause hypertension and this does not depend on the severity of scarring. Bilateral scarring may be associated with decreased kidney function and progressive CKD. It is caused by the following mechanisms:</p><p class="bulletIndent1"><span class="glyph">●</span>Acquired scarring due to reflux-related recurrent pyelonephritis</p><p class="bulletIndent1"><span class="glyph">●</span>Abnormal kidney development resulting in congenital renal hypodysplasia (see  <a class="medical medical_review" href="/d/html/6083.html" rel="external">"Renal hypodysplasia"</a>)</p><p></p><p class="headingAnchor" id="H17"><span class="h3">Kidney scarring</span><span class="headingEndMark"> — </span>VUR is a risk factor for recurrent pyelonephritis and potentially subsequent kidney scarring [<a href="#rid60">60-62</a>]. The risk of scarring increases with the severity of reflux. As a result, we continue to perform VCUG in at-risk children with febrile UTIs to detect possible VUR and provide treatment plans for those diagnosed with high-grade VUR (Grades III to V). (See  <a class="medical medical_review" href="/d/html/6095.html" rel="external">"Management of vesicoureteral reflux", section on 'Management'</a>.)</p><p>Support for this approach is provided by the previously discussed RIVUR trial that demonstrated an increase in subsequent kidney scarring detected by <a class="drug drug_general" data-topicid="9102" href="/d/drug information/9102.html" rel="external">dimercaptosuccinic acid</a> (DMSA) renal scans from a baseline rate of 4 to 11 percent at the end of the two-year follow-up [<a href="#rid11">11</a>]. This rate of kidney scarring is significantly lower than previously published retrospective data and may be due to the close monitoring of patients, including early diagnosis and prompt treatment of UTI, and a relatively short duration of follow-up of two years. In a subsequent publication, the risk of kidney scarring was associated with an older age at enrollment (26 versus 11 months), having a previous second UTI before enrollment, higher grade of VUR, and Hispanic ethnicity [<a href="#rid60">60</a>]. In this cohort, renal units with grade IV VUR had a much greater risk of developing scars than units without VUR (odds ratio [OR] 24.2, 95% CI 6.4-91.2).</p><p>Further support is provided by a meta-analysis of individual patient data from nine observational studies including 1280 children (0 to 18 years) with a first UTI. In this study, the risk of kidney scarring was also increased in children with VUR compared with children without VUR (41 versus 17 percent), and increased with increasing grades of VUR [<a href="#rid62">62</a>]. In this analysis, the presence of Grade IV or V VUR was the strongest predictor of kidney scarring, although only 4 percent of patients had this degree of reflux.</p><p class="bulletIndent1">In a study comparing patients <strong>with</strong> VUR from the RIVUR trial with children who had one or two febrile or symptomatic UTIs but <strong>no</strong> VUR from the CUTIE study, the risk of kidney scars was 10.2 versus 5.6 percent in children with VUR versus no VUR [<a href="#rid59">59</a>]. Although there was a trend towards increased risk of scarring with VUR, this difference was not statistically significant (adjusted odds ratio 2.05, 95% CI 0.86-4.87). These results should be interpreted with caution, as the number of patients with scarring in these two studies was small, and kidney scarring was not a primary end-point for these two studies.</p><p></p><p class="headingAnchor" id="H4216679888"><span class="h3">Congenital renal hypodysplasia</span><span class="headingEndMark"> — </span>Population-based studies have shown that renal hypoplasia or dysplasia resulting in reduced renal parenchymal mass may be observed in patients diagnosed prenatally with VUR [<a href="#rid63">63-65</a>]. In these studies, imaging typically demonstrated globally small kidneys with smooth kidney outlines consistent with renal hypodysplasia and not scarring [<a href="#rid63">63,64</a>]. In a large Japanese cohort of children with congenital kidney and urinary tract anomalies (CAKUT), the presence or history of VUR was not an associated risk factor with progression of chronic kidney disease (CKD) even though the rate of UTI was significantly higher in those with VUR as compared with those without VUR [<a href="#rid66">66</a>]. These data support the thesis that VUR is only a concomitant finding in patients with renal hypodysplasia and plays no causative role in the reduction of renal parenchyma. (See  <a class="medical medical_review" href="/d/html/6083.html" rel="external">"Renal hypodysplasia", section on 'Progression to end stage renal disease (ESRD)'</a>.)</p><p>However, despite the findings of the Japanese survey, we continue to be concerned that postnatal episodes of pyelonephritis may also play a role in kidney scarring in with congenital renal hypodysplasia. As a result, in our practice, we continue to treat patients with high-grade reflux (Grades III to V). (See  <a class="medical medical_review" href="/d/html/6095.html" rel="external">"Management of vesicoureteral reflux", section on 'Grades III to V'</a>.)</p><p class="headingAnchor" id="H1569449668"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/110818.html" rel="external">"Society guideline links: Vesicoureteral reflux"</a>.)</p><p class="headingAnchor" id="H2737911"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/16335.html" rel="external">"Patient education: Hydronephrosis in babies (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/17231.html" rel="external">"Patient education: Vesicoureteral reflux in children (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H19"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition and pathogenesis</strong> – Vesicoureteral reflux (VUR) is the retrograde passage of urine from the bladder into the upper urinary tract. VUR is divided into two categories based on the underlying pathogenesis (see <a class="local">'Definition and pathogenesis'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Primary VUR, the most common form of reflux, is due to incompetent or inadequate closure of the ureterovesical junction (UVJ) that contains a segment of the ureter within the bladder wall (intravesical ureter)  (<a class="graphic graphic_figure graphicRef54236" href="/d/graphic/54236.html" rel="external">figure 1</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Secondary VUR is a result of abnormally high voiding pressure in the bladder that results in failure of the closure of the UVJ during bladder contraction.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – Primary VUR occurs in approximately 1 percent of newborns. However, there is a significant rate of spontaneous resolution with growth, especially for patients with low-grade reflux (Grades I and II). (See <a class="local">'Epidemiology'</a> above and <a class="local">'Natural history'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Presentation</strong> – VUR can present prenatally or postnatally (see <a class="local">'Clinical presentation'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>VUR is diagnosed in approximately 15 to 20 percent of infants with prenatally diagnosed hydronephrosis. (See <a class="local">'Prenatal presentation'</a> above and  <a class="medical medical_review" href="/d/html/6105.html" rel="external">"Postnatal evaluation and management of hydronephrosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>VUR may be detected after a febrile urinary tract infection (UTI). (See <a class="local">'Postnatal presentation'</a> above and  <a class="medical medical_review" href="/d/html/5990.html" rel="external">"Urinary tract infections in infants and children older than one month: Clinical features and diagnosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Less commonly, VUR may be detected through family screening of an index case. (See <a class="local">'Testing family members'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Infants with prenatally diagnosed hydronephrosis</strong> – The evaluation of infants with prenatally diagnosed hydronephrosis is summarized in the figures  (<a class="graphic graphic_algorithm graphicRef74670 graphicRef69172" href="/d/graphic/74670.html" rel="external">algorithm 1A-B</a>) and discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/6105.html" rel="external">"Postnatal evaluation and management of hydronephrosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Infants and children with UTIs </strong>– Indications for performing voiding cystourethrogram (VCUG) after a UTI in infants and children are reviewed separately. (See  <a class="medical medical_review" href="/d/html/5991.html" rel="external">"Urinary tract infections in infants older than one month and children less than two years: Acute management, imaging, and prognosis", section on 'Voiding cystourethrogram'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis </strong>– The diagnosis of VUR is established with contrast voiding cystourethrogram (VCUG) demonstrating reflux of urine from the bladder to the upper urinary tract. Alternative imaging modalities that are less commonly used to diagnose VUR include contrast-enhanced voiding urosonography (ceVUS) or radionuclide cystogram (RNC). (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severity </strong>– Established grading systems are used to categorize the severity of VUR based upon the degree of retrograde filling and dilation of the renal collecting system  (<a class="graphic graphic_figure graphicRef67039" href="/d/graphic/67039.html" rel="external">figure 2</a>). (See <a class="local">'Grading'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Further evaluation</strong> – Once VUR is diagnosed, additional evaluation should be performed, including (see <a class="local">'Further evaluation'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Measurements of height, weight, and blood pressure.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Assessment for symptoms of bladder or bowel dysfunction (eg, urinary frequency and urgency, daytime wetting, constipation, and encopresis).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Laboratory tests, including urinalysis in all patients and serum creatinine if there is bilateral involvement or a solitary kidney.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Kidney ultrasound, if not already performed.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9102" href="/d/drug information/9102.html" rel="external">Dimercaptosuccinic acid</a> (DMSA) renal scan in select patients.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Assessment for VUR in younger siblings or offspring of the index case. (See <a class="local">'Testing family members'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complications</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Children with VUR are at risk for recurrent febrile or symptomatic UTIs, especially those with more severe VUR. (See <a class="local">'Recurrent urinary tract infection'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Loss of renal parenchyma is a common finding in patients with VUR. It may lead to decreased kidney function, and in some affected individuals with severe bilateral involvement to chronic kidney disease (CKD). Reduction in renal parenchyma is caused by the following mechanisms:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Acquired scarring is caused by renal parenchymal infection, which can occur in those with any grade of reflux, but is more common in those with higher VUR grades (III to V). (See <a class="local">'Kidney scarring'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Congenital renal hypodysplasia. (See <a class="local">'Congenital renal hypodysplasia'</a> above.)</p><p></p><p></p><p class="headingAnchor" id="H19374488"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges John T Herrin, MBBS, FRACP, and Gordon McLorie, MD, FRCSC, FAAP, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Ramage IJ, Schuckett B, McLorie GA, Geary DF. Primary vesicoureteric reflux diagnosed in the 1st month of life. Pediatr Nephrol 1999; 13:716.</a></li><li><a class="nounderline abstract_t">Willemsen J, Nijman RJ. Vesicoureteral reflux and videourodynamic studies: results of a prospective study. Urology 2000; 55:939.</a></li><li><a class="nounderline abstract_t">Hiraoka M, Hori C, Tsukahara H, et al. Vesicoureteral reflux in male and female neonates as detected by voiding ultrasonography. Kidney Int 1999; 55:1486.</a></li><li><a class="nounderline abstract_t">van Eerde AM, Meutgeert MH, de Jong TP, Giltay JC. Vesico-ureteral reflux in children with prenatally detected hydronephrosis: a systematic review. Ultrasound Obstet Gynecol 2007; 29:463.</a></li><li><a class="nounderline abstract_t">Skoog SJ, Peters CA, Arant BS Jr, et al. Pediatric Vesicoureteral Reflux Guidelines Panel Summary Report: Clinical Practice Guidelines for Screening Siblings of Children With Vesicoureteral Reflux and Neonates/Infants With Prenatal Hydronephrosis. J Urol 2010; 184:1145.</a></li><li><a class="nounderline abstract_t">Hoberman A, Charron M, Hickey RW, et al. Imaging studies after a first febrile urinary tract infection in young children. N Engl J Med 2003; 348:195.</a></li><li><a class="nounderline abstract_t">Chand DH, Rhoades T, Poe SA, et al. Incidence and severity of vesicoureteral reflux in children related to age, gender, race and diagnosis. J Urol 2003; 170:1548.</a></li><li><a class="nounderline abstract_t">Montini G, Rigon L, Zucchetta P, et al. Prophylaxis after first febrile urinary tract infection in children? A multicenter, randomized, controlled, noninferiority trial. Pediatrics 2008; 122:1064.</a></li><li><a class="nounderline abstract_t">Roussey-Kesler G, Gadjos V, Idres N, et al. Antibiotic prophylaxis for the prevention of recurrent urinary tract infection in children with low grade vesicoureteral reflux: results from a prospective randomized study. J Urol 2008; 179:674.</a></li><li><a class="nounderline abstract_t">Yeung CK, Godley ML, Dhillon HK, et al. The characteristics of primary vesico-ureteric reflux in male and female infants with pre-natal hydronephrosis. Br J Urol 1997; 80:319.</a></li><li><a class="nounderline abstract_t">RIVUR Trial Investigators, Hoberman A, Greenfield SP, et al. Antimicrobial prophylaxis for children with vesicoureteral reflux. N Engl J Med 2014; 370:2367.</a></li><li><a class="nounderline abstract_t">Kaefer M, Curran M, Treves ST, et al. Sibling vesicoureteral reflux in multiple gestation births. Pediatrics 2000; 105:800.</a></li><li><a class="nounderline abstract_t">Darlow JM, Darlay R, Dobson MG, et al. Genome-wide linkage and association study implicates the 10q26 region as a major genetic contributor to primary nonsyndromic vesicoureteric reflux. Sci Rep 2017; 7:14595.</a></li><li><a class="nounderline abstract_t">Gbadegesin RA, Brophy PD, Adeyemo A, et al. TNXB mutations can cause vesicoureteral reflux. J Am Soc Nephrol 2013; 24:1313.</a></li><li><a class="nounderline abstract_t">Beiraghdar F, Rostami Z, Panahi Y, et al. Vesicourethral reflux in pediatrics with hypermobility syndrome. Nephrourol Mon 2013; 5:924.</a></li><li><a class="nounderline abstract_t">Onal B, Miao X, Ozonoff A, et al. Protective locus against renal scarring on chromosome 11 in affected sib pairs with familial vesicoureteral reflux identified by single nucleotide polymorphism linkage analysis. J Urol 2012; 188:1467.</a></li><li><a class="nounderline abstract_t">Zaffanello M, Tardivo S, Cataldi L, et al. Genetic susceptibility to renal scar formation after urinary tract infection: a systematic review and meta-analysis of candidate gene polymorphisms. Pediatr Nephrol 2011; 26:1017.</a></li><li><a class="nounderline abstract_t">Liang D, McHugh KM, Brophy PD, et al. DNA copy number variations in children with vesicoureteral reflux and urinary tract infections. PLoS One 2019; 14:e0220617.</a></li><li><a class="nounderline abstract_t">Shaikh N, Hoberman A, Keren R, et al. Recurrent Urinary Tract Infections in Children With Bladder and Bowel Dysfunction. Pediatrics 2016; 137.</a></li><li><a class="nounderline abstract_t">Homayoon K, Chen JJ, Cummings JM, Steinhardt GF. Voiding dysfunction: outcome in infants with congenital vesicoureteral reflux. Urology 2005; 66:1091.</a></li><li><a class="nounderline abstract_t">Sillén U, Brandström P, Jodal U, et al. The Swedish reflux trial in children: v. Bladder dysfunction. J Urol 2010; 184:298.</a></li><li><a class="nounderline abstract_t">Hong YK, Altobelli E, Borer JG, et al. Urodynamic abnormalities in toilet trained children with primary vesicoureteral reflux. J Urol 2011; 185:1863.</a></li><li><a class="nounderline abstract_t">Carpenter MA, Hoberman A, Mattoo TK, et al. The RIVUR trial: profile and baseline clinical associations of children with vesicoureteral reflux. Pediatrics 2013; 132:e34.</a></li><li><a class="nounderline abstract_t">Vates TS, Shull MJ, Underberg-Davis SJ, Fleisher MH. Complications of voiding cystourethrography in the evaluation of infants with prenatally detected hydronephrosis. J Urol 1999; 162:1221.</a></li><li><a class="nounderline abstract_t">Frimberger D, Mercado-Deane MG, Section on Urology, Section on Radiolgy. Establishing a Standard Protocol for the Voiding Cystourethrography. Pediatrics 2016; 138.</a></li><li><a class="nounderline abstract_t">Medical versus surgical treatment of primary vesicoureteral reflux: report of the International Reflux Study Committee. Pediatrics 1981; 67:392.</a></li><li><a class="nounderline abstract_t">Greenfield SP, Carpenter MA, Chesney RW, et al. The RIVUR voiding cystourethrogram pilot study: experience with radiologic reading concordance. J Urol 2012; 188:1608.</a></li><li><a class="nounderline abstract_t">Metcalfe CB, Macneily AE, Afshar K. Reliability assessment of international grading system for vesicoureteral reflux. J Urol 2012; 188:1490.</a></li><li><a class="nounderline abstract_t">Willi U, Treves S. Radionuclide voiding cystography. Urol Radiol 1983; 5:161.</a></li><li><a class="nounderline abstract_t">Cooper CS, Birusingh KK, Austin JC, et al. Distal ureteral diameter measurement objectively predicts vesicoureteral reflux outcome. J Pediatr Urol 2013; 9:99.</a></li><li><a class="nounderline abstract_t">Cooper CS, Alexander SE, Kieran K, Storm DW. Utility of the distal ureteral diameter on VCUG for grading VUR. J Pediatr Urol 2015; 11:183.e1.</a></li><li><a class="nounderline abstract_t">Arlen AM, Kirsch AJ, Leong T, Cooper CS. Validation of the ureteral diameter ratio for predicting early spontaneous resolution of primary vesicoureteral reflux. J Pediatr Urol 2017; 13:383.e1.</a></li><li><a class="nounderline abstract_t">Arlen AM, Leong T, Wu CQ, et al. Predicting Breakthrough Urinary Tract Infection: Comparative Analysis of Vesicoureteral Reflux Index, Reflux Grade and Ureteral Diameter Ratio. J Urol 2020; 204:572.</a></li><li><a class="nounderline abstract_t">Garcia-Roig M, Ridley DE, McCracken C, et al. Vesicoureteral Reflux Index: Predicting Primary Vesicoureteral Reflux Resolution in Children Diagnosed after Age 24 Months. J Urol 2017; 197:1150.</a></li><li><a class="nounderline abstract_t">Shaikh N, Spingarn RB, Hum SW. Dimercaptosuccinic acid scan or ultrasound in screening for vesicoureteral reflux among children with urinary tract infections. Cochrane Database Syst Rev 2016; 7:CD010657.</a></li><li><a class="nounderline abstract_t">Birkelund Y, Klemetsen Ø, Jacobsen SK, et al. Vesicoureteral reflux in children: a phantom study of microwave heating and radiometric thermometry of pediatric bladder. IEEE Trans Biomed Eng 2011; 58:3269.</a></li><li><a class="nounderline abstract_t">Arthurs OJ, Edwards AD, Joubert I, et al. Interactive magnetic resonance voiding cystourethrography (iMRVC) for vesicoureteric reflux (VUR) in unsedated infants: a feasibility study. Eur Radiol 2011; 21:1874.</a></li><li><a class="nounderline abstract_t">Fallah MM, Falahati M, Mohammadi A, et al. Comparative study of color Doppler voiding urosonography without contrast enhancement and direct radionuclide voiding cystography for diagnosis of vesicoureteric reflux in children. J Ultrasound Med 2012; 31:55.</a></li><li><a class="nounderline abstract_t">Duran C, del Riego J, Riera L, et al. Voiding urosonography including urethrosonography: high-quality examinations with an optimised procedure using a second-generation US contrast agent. Pediatr Radiol 2012; 42:660.</a></li><li><a class="nounderline abstract_t">Papadopoulou F, Anthopoulou A, Siomou E, et al. Harmonic voiding urosonography with a second-generation contrast agent for the diagnosis of vesicoureteral reflux. Pediatr Radiol 2009; 39:239.</a></li><li><a class="nounderline abstract_t">Keir MJ, Lambert HJ, Coulthard MG. Maximizing the sensitivity of the indirect radionuclide cystogram: a retrospective audit. Pediatr Nephrol 2013; 28:2137.</a></li><li><a class="nounderline abstract_t">D'Souza MK, Verma NS, A R PK, et al. Detecting reflux: does ureteric jet Doppler waveform have a role? Pediatr Nephrol 2013; 28:1821.</a></li><li><a class="nounderline abstract_t">Kis E, Nyitrai A, Várkonyi I, et al. Voiding urosonography with second-generation contrast agent versus voiding cystourethrography. Pediatr Nephrol 2010; 25:2289.</a></li><li><a class="nounderline abstract_t">Vasanawala SS, Kennedy WA, Ganguly A, et al. MR voiding cystography for evaluation of vesicoureteral reflux. AJR Am J Roentgenol 2009; 192:W206.</a></li><li><a class="nounderline abstract_t">Peters CA, Skoog SJ, Arant BS Jr, et al. Summary of the AUA Guideline on Management of Primary Vesicoureteral Reflux in Children. J Urol 2010; 184:1134.</a></li><li><a class="nounderline abstract_t">Tekgül S, Riedmiller H, Hoebeke P, et al. EAU guidelines on vesicoureteral reflux in children. Eur Urol 2012; 62:534.</a></li><li><a class="nounderline abstract_t">Hunziker M, Colhoun E, Puri P. Renal cortical abnormalities in siblings of index patients with vesicoureteral reflux. Pediatrics 2014; 133:e933.</a></li><li><a class="nounderline abstract_t">Wan J, Greenfield SP, Ng M, et al. Sibling reflux: a dual center retrospective study. J Urol 1996; 156:677.</a></li><li><a class="nounderline abstract_t">Menezes M, Puri P. Familial vesicoureteral reflux--is screening beneficial? J Urol 2009; 182:1673.</a></li><li><a class="nounderline abstract_t">Hunziker M, Puri P. Familial vesicoureteral reflux and reflux related morbidity in relatives of index patients with high grade vesicoureteral reflux. J Urol 2012; 188:1463.</a></li><li><a class="nounderline abstract_t">Elder JS, Peters CA, Arant BS Jr, et al. Pediatric Vesicoureteral Reflux Guidelines Panel summary report on the management of primary vesicoureteral reflux in children. J Urol 1997; 157:1846.</a></li><li><a class="nounderline abstract_t">Sjöström S, Sillén U, Jodal U, et al. Predictive factors for resolution of congenital high grade vesicoureteral reflux in infants: results of univariate and multivariate analyses. J Urol 2010; 183:1177.</a></li><li><a class="nounderline abstract_t">Estrada CR Jr, Passerotti CC, Graham DA, et al. Nomograms for predicting annual resolution rate of primary vesicoureteral reflux: results from 2,462 children. J Urol 2009; 182:1535.</a></li><li><a class="nounderline abstract_t">Sjöström S, Sillén U, Bachelard M, et al. Spontaneous resolution of high grade infantile vesicoureteral reflux. J Urol 2004; 172:694.</a></li><li><a class="nounderline abstract_t">Godley ML, Desai D, Yeung CK, et al. The relationship between early renal status, and the resolution of vesico-ureteric reflux and bladder function at 16 months. BJU Int 2001; 87:457.</a></li><li><a class="nounderline abstract_t">Smellie JM, Jodal U, Lax H, et al. Outcome at 10 years of severe vesicoureteric reflux managed medically: Report of the International Reflux Study in Children. J Pediatr 2001; 139:656.</a></li><li><a class="nounderline abstract_t">Ismaili K, Hall M, Piepsz A, et al. Primary vesicoureteral reflux detected in neonates with a history of fetal renal pelvis dilatation: a prospective clinical and imaging study. J Pediatr 2006; 148:222.</a></li><li><a class="nounderline abstract_t">Upadhyay J, McLorie GA, Bolduc S, et al. Natural history of neonatal reflux associated with prenatal hydronephrosis: long-term results of a prospective study. J Urol 2003; 169:1837.</a></li><li><a class="nounderline abstract_t">Keren R, Shaikh N, Pohl H, et al. Risk Factors for Recurrent Urinary Tract Infection and Renal Scarring. Pediatrics 2015; 136:e13.</a></li><li><a class="nounderline abstract_t">Mattoo TK, Chesney RW, Greenfield SP, et al. Renal Scarring in the Randomized Intervention for Children with Vesicoureteral Reflux (RIVUR) Trial. Clin J Am Soc Nephrol 2016; 11:54.</a></li><li><a class="nounderline abstract_t">Shaikh N, Ewing AL, Bhatnagar S, Hoberman A. Risk of renal scarring in children with a first urinary tract infection: a systematic review. Pediatrics 2010; 126:1084.</a></li><li><a class="nounderline abstract_t">Shaikh N, Craig JC, Rovers MM, et al. Identification of children and adolescents at risk for renal scarring after a first urinary tract infection: a meta-analysis with individual patient data. JAMA Pediatr 2014; 168:893.</a></li><li><a class="nounderline abstract_t">Patterson LT, Strife CF. Acquired versus congenital renal scarring after childhood urinary tract infection. J Pediatr 2000; 136:2.</a></li><li><a class="nounderline abstract_t">Wennerström M, Hansson S, Jodal U, Stokland E. Primary and acquired renal scarring in boys and girls with urinary tract infection. J Pediatr 2000; 136:30.</a></li><li><a class="nounderline abstract_t">Marra G, Oppezzo C, Ardissino G, et al. Severe vesicoureteral reflux and chronic renal failure: a condition peculiar to male gender? Data from the ItalKid Project. J Pediatr 2004; 144:677.</a></li><li><a class="nounderline abstract_t">Ishikura K, Uemura O, Hamasaki Y, et al. Insignificant impact of VUR on the progression of CKD in children with CAKUT. Pediatr Nephrol 2016; 31:105.</a></li></ol></div><div id="topicVersionRevision">Topic 6094 Version 44.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10576793" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Primary vesicoureteric reflux diagnosed in the 1st month of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10840114" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Vesicoureteral reflux and videourodynamic studies: results of a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10201014" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Vesicoureteral reflux in male and female neonates as detected by voiding ultrasonography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17390310" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Vesico-ureteral reflux in children with prenatally detected hydronephrosis: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20650494" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Pediatric Vesicoureteral Reflux Guidelines Panel Summary Report: Clinical Practice Guidelines for Screening Siblings of Children With Vesicoureteral Reflux and Neonates/Infants With Prenatal Hydronephrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12529459" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Imaging studies after a first febrile urinary tract infection in young children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14501657" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Incidence and severity of vesicoureteral reflux in children related to age, gender, race and diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18977988" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Prophylaxis after first febrile urinary tract infection in children? A multicenter, randomized, controlled, noninferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18082208" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Antibiotic prophylaxis for the prevention of recurrent urinary tract infection in children with low grade vesicoureteral reflux: results from a prospective randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9284209" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The characteristics of primary vesico-ureteric reflux in male and female infants with pre-natal hydronephrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24795142" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Antimicrobial prophylaxis for children with vesicoureteral reflux.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10742323" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Sibling vesicoureteral reflux in multiple gestation births.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29097723" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Genome-wide linkage and association study implicates the 10q26 region as a major genetic contributor to primary nonsyndromic vesicoureteric reflux.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23620400" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : TNXB mutations can cause vesicoureteral reflux.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24350094" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Vesicourethral reflux in pediatrics with hypermobility syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22906679" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Protective locus against renal scarring on chromosome 11 in affected sib pairs with familial vesicoureteral reflux identified by single nucleotide polymorphism linkage analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21116828" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Genetic susceptibility to renal scar formation after urinary tract infection: a systematic review and meta-analysis of candidate gene polymorphisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31404082" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : DNA copy number variations in children with vesicoureteral reflux and urinary tract infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26647376" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Recurrent Urinary Tract Infections in Children With Bladder and Bowel Dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16286132" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Voiding dysfunction: outcome in infants with congenital vesicoureteral reflux.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20488486" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The Swedish reflux trial in children: v. Bladder dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21421235" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Urodynamic abnormalities in toilet trained children with primary vesicoureteral reflux.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23753091" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The RIVUR trial: profile and baseline clinical associations of children with vesicoureteral reflux.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10458471" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Complications of voiding cystourethrography in the evaluation of infants with prenatally detected hydronephrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Establishing a Standard Protocol for the Voiding Cystourethrography</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7017578" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Medical versus surgical treatment of primary vesicoureteral reflux: report of the International Reflux Study Committee.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22910235" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The RIVUR voiding cystourethrogram pilot study: experience with radiologic reading concordance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22906646" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Reliability assessment of international grading system for vesicoureteral reflux.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6226140" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Radionuclide voiding cystography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22236467" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Distal ureteral diameter measurement objectively predicts vesicoureteral reflux outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26189589" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Utility of the distal ureteral diameter on VCUG for grading VUR.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28256423" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Validation of the ureteral diameter ratio for predicting early spontaneous resolution of primary vesicoureteral reflux.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32243241" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Predicting Breakthrough Urinary Tract Infection: Comparative Analysis of Vesicoureteral Reflux Index, Reflux Grade and Ureteral Diameter Ratio.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27939835" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Vesicoureteral Reflux Index: Predicting Primary Vesicoureteral Reflux Resolution in Children Diagnosed after Age 24 Months.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27378557" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Dimercaptosuccinic acid scan or ultrasound in screening for vesicoureteral reflux among children with urinary tract infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21900069" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Vesicoureteral reflux in children: a phantom study of microwave heating and radiometric thermometry of pediatric bladder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21499959" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Interactive magnetic resonance voiding cystourethrography (iMRVC) for vesicoureteric reflux (VUR) in unsedated infants: a feasibility study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22215770" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Comparative study of color Doppler voiding urosonography without contrast enhancement and direct radionuclide voiding cystography for diagnosis of vesicoureteric reflux in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22580901" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Voiding urosonography including urethrosonography: high-quality examinations with an optimised procedure using a second-generation US contrast agent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19096835" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Harmonic voiding urosonography with a second-generation contrast agent for the diagnosis of vesicoureteral reflux.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23771301" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Maximizing the sensitivity of the indirect radionuclide cystogram: a retrospective audit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23588743" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Detecting reflux: does ureteric jet Doppler waveform have a role?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20686902" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Voiding urosonography with second-generation contrast agent versus voiding cystourethrography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19380524" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : MR voiding cystography for evaluation of vesicoureteral reflux.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20650499" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Summary of the AUA Guideline on Management of Primary Vesicoureteral Reflux in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22698573" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : EAU guidelines on vesicoureteral reflux in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24664090" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Renal cortical abnormalities in siblings of index patients with vesicoureteral reflux.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8683758" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Sibling reflux: a dual center retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19692047" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Familial vesicoureteral reflux--is screening beneficial?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22906681" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Familial vesicoureteral reflux and reflux related morbidity in relatives of index patients with high grade vesicoureteral reflux.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9112544" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Pediatric Vesicoureteral Reflux Guidelines Panel summary report on the management of primary vesicoureteral reflux in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20096864" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Predictive factors for resolution of congenital high grade vesicoureteral reflux in infants: results of univariate and multivariate analyses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19683762" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Nomograms for predicting annual resolution rate of primary vesicoureteral reflux: results from 2,462 children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15247764" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Spontaneous resolution of high grade infantile vesicoureteral reflux.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11298034" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : The relationship between early renal status, and the resolution of vesico-ureteric reflux and bladder function at 16 months.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11713442" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Outcome at 10 years of severe vesicoureteric reflux managed medically: Report of the International Reflux Study in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16492433" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Primary vesicoureteral reflux detected in neonates with a history of fetal renal pelvis dilatation: a prospective clinical and imaging study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12686858" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Natural history of neonatal reflux associated with prenatal hydronephrosis: long-term results of a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26055855" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Risk Factors for Recurrent Urinary Tract Infection and Renal Scarring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26555605" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Renal Scarring in the Randomized Intervention for Children with Vesicoureteral Reflux (RIVUR) Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21059720" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Risk of renal scarring in children with a first urinary tract infection: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25089634" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Identification of children and adolescents at risk for renal scarring after a first urinary tract infection: a meta-analysis with individual patient data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10636963" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Acquired versus congenital renal scarring after childhood urinary tract infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10636970" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Primary and acquired renal scarring in boys and girls with urinary tract infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15127014" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Severe vesicoureteral reflux and chronic renal failure: a condition peculiar to male gender? Data from the ItalKid Project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26404649" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Insignificant impact of VUR on the progression of CKD in children with CAKUT.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
